Sebastian Kurz, MD, PhD, FCCP
Associate Professor TermCards
About
Research
Publications
2026
Synergistic activity of dual β-lactams against <em>Mycobacterium avium</em> complex
Shin E, Dousa KM, Nantongo M, Kurz SG, Holland SM, Kreiswirth BN, Bonomo RA. Synergistic activity of dual β-lactams against Mycobacterium avium complex. Microbiology Spectrum 2026, 14: e04001-25. DOI: 10.1128/spectrum.04001-25.Peer-Reviewed Original ResearchThe Mitral Valve and the Lungs.
Pradhan NM, Wessler BS, Hill N, Kurz S. The Mitral Valve and the Lungs. Chest 2026, 169: 744-753. PMID: 41297586, DOI: 10.1016/j.chest.2025.11.016.Peer-Reviewed Original Research
2025
The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials
Dousa K, Shin E, Kurz S, Rubin E, Holland S, Olivier K, Daley C, Kreiswirth B, Pottinger P, Bonomo R. The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials. Clinical Infectious Diseases 2025, 82: e135-e145. PMID: 41026774, DOI: 10.1093/cid/ciaf547.Peer-Reviewed Original ResearchB-lactam antibioticsB-lactamaseB-lactamMycobacterium abscessusClinical trialsIn vitro susceptibility studiesB-lactamase inhibitorsDual inhibitionStructural lung diseaseLaboratory insightsNon-tuberculous mycobacteriaPublished clinical casesInhibitor combinationsBiochemical characterizationLung diseaseTreatment challengesCell wall biologyClinical casesL,D-transpeptidasesClinical experienceBlaMabClinical applicationAbscessusFunctional impactPeptidoglycan crosslinkingExploring β-lactam interactions with DacB1: unraveling optimal therapies for combating drug-resistant Mycobacterium tuberculosis
Nantongo M, Nguyen D, Shin E, Bethel C, Taracila M, Dousa K, Li Q, Fletcher S, Kurz S, Kreiswirth B, Boom W, Holland S, Rubin E, Bonomo R. Exploring β-lactam interactions with DacB1: unraveling optimal therapies for combating drug-resistant Mycobacterium tuberculosis. MBio 2025, 16: e01372-25. PMID: 40637416, PMCID: PMC12345272, DOI: 10.1128/mbio.01372-25.Peer-Reviewed Original ResearchConceptsB-lactamase inhibitorsDrug-resistant TBB-lactam antibioticsB-lactamMinimum inhibitory concentrationTB treatmentB-lactamaseDifferential scanning fluorimetryPeptidoglycan biosynthesisPublic health threatExploration of alternative therapeutic strategiesTreatment success rateCurrent treatment optionsDrug-resistant Mycobacterium tuberculosisD,D-carboxypeptidaseAcyl-enzyme adductCell wall synthesisAlternative therapeutic strategiesTB-related mortalityDrug-resistant strainsGlobal public health threatAcyl-enzyme formationDrug-resistant MTB strainsCombination therapyInhibitor combinationsP-1503. Dual β-Lactam Approach for Treatment of Mycobacterium abscessus Infections in Adults – Results in 19 Patients
Kalyatanda G, Dousa K, Lyons H, Mardourian M, Rhodes J, Iakovidis A, El-Helou G, Wilson B, Daley C, Holland S, Kreiswirth B, Nguyen D, Shin E, Kurz S, Johnson J, Bonomo R. P-1503. Dual β-Lactam Approach for Treatment of Mycobacterium abscessus Infections in Adults – Results in 19 Patients. Open Forum Infectious Diseases 2025, 12: ofae631.1672. PMCID: PMC11778049, DOI: 10.1093/ofid/ofae631.1672.Peer-Reviewed Original ResearchSubspecies abscessusB-lactamAssociated with high cure ratesIn vitro susceptibility resultsMulti-drug regimensCurrent treatment regimensSolid organ transplantationHigh cure ratesTime to initiationOptimize treatment outcomesMab infectionSynergy testClinical cureImmunocompromised patientsPulmonary infectionDiscontinued treatmentTreatment regimensCase reportClinical outcomesCure rateImmunocompromised individualsAutoimmune diseasesTreatment successEarly treatmentCulture conversionP-788. Exploring β-Lactam Interactions with DacB1: Unraveling Optimal Therapies for Combating Drug-Resistant Mycobacterium tuberculosis
Nantongo M, Nguyen D, Shin E, Bethel C, Taracila M, Dousa K, Kurz S, Nguyen L, Kreiswirth B, Boom W, Bonomo R. P-788. Exploring β-Lactam Interactions with DacB1: Unraveling Optimal Therapies for Combating Drug-Resistant Mycobacterium tuberculosis. Open Forum Infectious Diseases 2025, 12: ofae631.982. PMCID: PMC11778675, DOI: 10.1093/ofid/ofae631.982.Peer-Reviewed Original ResearchMinimum inhibitory concentrationAcyl-enzyme adductOxyanion holeB-lactamB-lactamasePeptidoglycan synthesis pathwayCarbonyl groupHydrophobic interactionsElectrospray ionization mass spectrometryAcyl-enzyme formationB-lactam antibioticsMichaelis-Menten complexC1‐methyl groupProtein motifsPeptidoglycan biosynthesisDrug-resistant Mycobacterium tuberculosisIonization mass spectrometryPeptidoglycan synthesisD-carboxypeptidaseAnalysis of meropenemB-lactamase inhibitorsClinical isolatesBroth microdilutionClinically achievable concentrationsSynthesis pathway
2024
Durlobactam in combination with β-lactams to combat Mycobacterium abscessus
Shin E, Dousa K, Taracila M, Bethel C, Nantongo M, Nguyen D, Akusobi C, Kurz S, Plummer M, Daley C, Holland S, Rubin E, Bulitta J, Boom W, Kreiswirth B, Bonomo R. Durlobactam in combination with β-lactams to combat Mycobacterium abscessus. Antimicrobial Agents And Chemotherapy 2024, 69: e01174-24. PMID: 39714147, PMCID: PMC11823594, DOI: 10.1128/aac.01174-24.Peer-Reviewed Original ResearchSynergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus
Dousa K, Shin E, Kurz S, Plummer M, Nantongo M, Bethel C, Taracila M, Nguyen D, Kreiswith B, Daley C, Remy K, Holland S, Bonomo R. Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus. MBio 2024, 15: e00609-24. PMID: 38742824, PMCID: PMC11237399, DOI: 10.1128/mbio.00609-24.Peer-Reviewed Original ResearchConceptsD,D-carboxypeptidaseMinimum inhibitory concentrationB-lactamPenicillin-binding-proteinCell wall synthesisL,D-transpeptidasesResistance to common antibioticsLowest minimum inhibitory concentrationWall synthesisCystic fibrosisD-carboxypeptidaseMass spectrometry analysisB-lactamaseThioester bondRate of treatment failureCell-based assaysMultiple antibioticsB-lactam ringsCommon antibioticsD-transpeptidasesB-lactamase inhibitorsCysteine residuesTime-kill studiesStructural lung diseaseMultidrug-resistant tuberculosisDurlobactam, a Diazabicyclooctane β‑Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of Mycobacterium tuberculosis
Nantongo M, Nguyen D, Bethel C, Taracila M, Li Q, Dousa K, Shin E, Kurz S, Nguyen L, Kreiswirth B, Boom W, Plummer M, Bonomo R. Durlobactam, a Diazabicyclooctane β‑Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of Mycobacterium tuberculosis. ACS Infectious Diseases 2024, 10: 1767-1779. PMID: 38619138, DOI: 10.1021/acsinfecdis.4c00119.Peer-Reviewed Original ResearchConceptsESI-MSElectrospray ionization mass spectrometryIonization mass spectrometryB-lactamase inhibitorsAcyl-enzyme complexMycobacterial cell wall synthesisMolecular dockingMass spectrometryActive siteInhibit BlaCPeptidoglycan transpeptidaseDiazabicyclooctaneSynthesisAntibiotic susceptibility testingCell wall synthesisInhibition kineticsDrug targetsB-lactamaseDurlobactamSusceptibility testingComplexDockingSpectrometryWall synthesisPeptidoglycan synthesis
2023
Eradicating Pulmonary Mycobacterium abscessus: The Promise of Dual β-Lactam Therapy
Alahmdi B, Dousa K, Kurz S, Kaufman A, Bonomo R, Taimur S. Eradicating Pulmonary Mycobacterium abscessus: The Promise of Dual β-Lactam Therapy. Open Forum Infectious Diseases 2023, 10: ofad312. PMID: 37383246, PMCID: PMC10296056, DOI: 10.1093/ofid/ofad312.Peer-Reviewed Original Research
News
News
- October 01, 2025
Yale PCCSM Faculty Earn National Recognition at CHEST Annual Meeting
- April 14, 2025
Expanded Yale Center Enhances Access to Asthma, COPD, and Bronchiectasis Diagnosis, Care, and Research
- January 02, 2025
Yale Department of Internal Medicine Faculty Promotions and Appointments (January 2025)
- November 25, 2024
Celebrating Leadership and Education: Yale Faculty Recognized at CHEST Annual Meeting